{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:04:47Z","timestamp":1780639487157,"version":"3.54.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pediatric immune thrombocytopenia (ITP) is an autoimmune condition involving platelet destruction. While most cases resolve spontaneously, 20%\u201330% progress to chronic disease (cITP), necessitating early risk prediction. Current prognostic models for childhood ITP lack platelet-specific immunological markers. This study aimed to develop and validate a predictive model for chronic\/persistent ITP(c\/pITP) integrating clinical factors and anti-platelet glycoprotein antibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively analyzed 381 children with newly diagnosed ITP (2022\u20132024). Patients were randomly allocated into training (\n                      <jats:italic>n<\/jats:italic>\n                      = 266) and test (\n                      <jats:italic>n<\/jats:italic>\n                      = 115) sets (7:3 ratio, seed = 42). Missing data were addressed via multiple imputation (m = 5). Predictors were selected through univariate analysis (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.1), LASSO regression with 10-fold cross-validation, and bootstrap stability assessment (\u03bb.1se, B = 1,000, selection frequency \u2265 90%). Candidate models were compared using bootstrap optimism correction and the Equivalent Parsimony Principle. The final model was evaluated on the independent test set for discrimination (AUC), calibration (Hosmer\u2013Lemeshow test), and clinical utility (decision curve analysis).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fourteen highly stable predictors were identified; the top three were platelet count (PLT, 100%), recent infection or vaccination history (IOV, 100%), and anti-GPIIb antibody status (99.9%). The final 4-variable model (age, IOV, PLT, anti-GPIIb) demonstrated good discrimination in the test set (AUC = 0.743; 95% CI: 0.650\u20130.836), with no evidence of overfitting (training AUC = 0.732). Calibration was satisfactory (Hosmer\u2013Lemeshow\n                      <jats:italic>P<\/jats:italic>\n                      = 0.859). At a low-risk threshold (predicted probability \u2264 15%), the negative predictive value reached 94.7%, facilitating the rule-out of chronic progression. Decision curve analysis confirmed positive net benefit across threshold probabilities of 0%\u201360%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This concise model incorporating anti-GPIIb antibody enables early risk stratification, primarily to identify children unlikely to develop c\/pITP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1832712","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:40:44Z","timestamp":1780638044000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a predictive model for chronic or persistent immune thrombocytopenia in children incorporating anti-glycoprotein IIb antibody: a retrospective cohort study utilizing LASSO regression and bootstrap stability analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Ximei","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Jiangxi Provincial Children's Hospital","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghui","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Jiangxi Provincial Cancer Hospital","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Ying","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Jiangxi Provincial Children's Hospital","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Jiangxi Provincial Children's Hospital","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Jiangxi Provincial Children's Hospital","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Jiangxi Provincial Children's Hospital","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangwei","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Jiangxi Provincial Children's Hospital","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1182\/blood.2023023601","article-title":"YAP1 regulates thrombopoiesis by binding to MYH9 in immune thrombocytopenia","volume":"144","author":"Hu","year":"2024","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1016\/j.jtha.2025.05.024","article-title":"Clinical evidence for antiglycoprotein IIbIIIa antibody-induced platelet desialylation in primary immune thrombocytopenia","volume":"23","author":"Schramm","year":"2025","journal-title":"J Thromb Haemost"},{"key":"B3","doi-asserted-by":"publisher","first-page":"103581","DOI":"10.1016\/j.critrevonc.2022.103581","article-title":"Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: a systematic review and meta-analysis","volume":"171","author":"Tjepkema","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.3324\/haematol.2022.282524","article-title":"Adolescents and young adults with newly diagnosed primary immune thrombocytopenia","volume":"108","author":"Schifferli","year":"2023","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e28840","DOI":"10.1002\/pbc.28840","article-title":"Fatigue perception in a cohort of children with chronic immune thrombocytopenia and their caregivers using the PedsQL MFS: real-life multicenter experience of the Italian association of pediatric hematology and oncology (AIEOP)","volume":"68","author":"Lassandro","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/bjh.17694","article-title":"Qualitative study to support the content validity of the immune thrombocytopenia (ITP) life quality index (ILQI)","volume":"194","author":"Cooper","year":"2021","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1111\/bjh.19615","article-title":"A novel scoring model for predicting efficacy and guiding individualised treatment in immune thrombocytopaenia","volume":"205","author":"Xu","year":"2024","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/j.scib.2023.08.001","article-title":"A life-threatening bleeding prediction model for immune thrombocytopenia based on personalized machine learning: a nationwide prospective cohort study","volume":"68","author":"An","year":"2023","journal-title":"Sci Bull (Beijing)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"B11","doi-asserted-by":"publisher","first-page":"b2393","DOI":"10.1136\/bmj.b2393","article-title":"Multiple imputation for missing data in epidemiological and clinical research: practical and theoretical considerations","volume":"338","author":"Sterne","year":"2009","journal-title":"Br Med J"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1002\/0471722146","volume-title":"Applied Logistic Regression","author":"Hosmer","year":"2000"},{"key":"B13","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decis Making"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3760\/cma.j.cn121090-20251031-00494","article-title":". Chinese guidelines for diagnosis and treatment of adult primary immune thrombocytopenia (2025 edition)","volume":"46","year":"2025","journal-title":"Chin J Hematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.13558\/j.cnki.issn1672-3686.2019.012.002","article-title":"Diagnosis and treatment protocol for primary immune thrombocytopenia in children (2019 edition)","volume":"17","year":"2019","journal-title":"Chin J Gen Pract"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American society of hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"B17","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12967-017-1317-2","article-title":"Flow cytometric immunobead assay for quantitative detection of platelet autoantibodies in immune thrombocytopenia patients","volume":"15","author":"Zhai","year":"2017","journal-title":"J Transl Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e574","DOI":"10.1097\/HS9.0000000000000574","article-title":"Immune thrombocytopenia: recent advances in pathogenesis and treatments","volume":"5","author":"Audia","year":"2021","journal-title":"Hemasphere"},{"key":"B19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.13201\/j.issn.1004-2806.2022.07.004","article-title":"Role of platelet-specific autoantibodies in clinical characteristics and prognostic evaluation of patients with immune thrombocytopenia","volume":"35","author":"Zhou","year":"2022","journal-title":"J Clin Hematol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.jtha.2023.12.006","article-title":"Machine learning models developed and internally validated for predicting chronicity in pediatric immune thrombocytopenia","volume":"22","author":"Ma","year":"2024","journal-title":"J Thromb Haemost"},{"key":"B21","doi-asserted-by":"publisher","first-page":"894","DOI":"10.13201\/j.issn.1004-2806.2025.11.011","article-title":"Analysis of influencing factors and model construction of chronic course of immune thrombocytopenia in children","volume":"38","author":"Yuxuan","year":"2025","journal-title":"J Clin Hematol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.16352\/j.issn.1001-6325.2024.01.0084","article-title":"Investigation on the risk of recurrent immune thrombocytopenia in children and establishment of a predictive model","volume":"44","author":"Shen","year":"2024","journal-title":"Basic Clin Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/jth.15125","article-title":"A clinical prediction score for transient versus persistent childhood immune thrombocytopenia","volume":"19","author":"Schmidt","year":"2021","journal-title":"J Thromb Haemost"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1679463","DOI":"10.3389\/fped.2025.1679463","article-title":"Study on the influencing factors of the first-line treatment response to primary immune thrombocytopenia in children","volume":"13","author":"Zhang","year":"2025","journal-title":"Front Pediatr"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e30094","DOI":"10.1002\/pbc.30094","article-title":"Anti-glycoprotein autoantibodies are related to bleeding severity in children with newly diagnosed ITP and very low platelet counts","volume":"70","author":"Dong","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.19746\/j.cnki.issn1009-2137.2023.05.030","article-title":"Clinical characteristics analysis of immune thrombocytopenia in children","volume":"31","author":"Ren","year":"2023","journal-title":"J Exp Hematol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1111\/apa.70090","article-title":"Immune thrombocytopenia in Finnish children and adolescents: a population-based cohort study","volume":"114","author":"Kulmala","year":"2025","journal-title":"Acta Paediatr"},{"key":"B28","doi-asserted-by":"publisher","first-page":"574","DOI":"10.19746\/j.cnki.issn.1009-2137.2021.02.042","article-title":"Clinical analysis of hospitalized children with primary immune thrombocytopenia","volume":"29","author":"Li","year":"2021","journal-title":"J Exp Hematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1111\/bjh.19405","article-title":"Protective effects of COVID-19 vaccination in splenectomized patients with immune thrombocytopenia","volume":"204","author":"Liu","year":"2024","journal-title":"Br J Haematol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"103605","DOI":"10.1016\/j.autrev.2024.103605","article-title":"Immune thrombocytopenia (ITP)\u2014could it be part of autoimmune\/inflammatory syndrome induced by adjuvants (ASIA)?","volume":"23","author":"David","year":"2024","journal-title":"Autoimmun Rev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1182\/blood-2023-181606","article-title":"Efficacy and safety of dapsone in primary immune thrombocytopenia: results of a randomized, placebo-controlled multicenter trial and of a single-arm, emulated trial in the prospective, multicenter Carmen-France registry","volume":"142","author":"Larue","year":"2023","journal-title":"Blood"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1832712\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:40:50Z","timestamp":1780638050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1832712\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":31,"alternative-id":["10.3389\/fped.2026.1832712"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1832712","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"article-number":"1832712"}}